Business Development

Partnership & Licensing Opportunities

We are actively presenting ErpeCream® to strategic partners at key industry conferences and through direct BD outreach. Our non-confidential deck and Phase IIb study summary are available upon request.

PATHWAY A

Distributors (Consumer Products)

For distributors and commercial partners — Products available today, registered and ready for global distribution.

Available Products

ErpeCream® (HSV-2)
CPNP + UK.GOV registered
ErpeLips™ (HSV-1)
CPNP registered - 3ml pocket format

Target Channels

Benefits

    PATHWAY B

    Co-Development / Licensing

    For pharmaceutical partners — Phase IIb in progress, ready for licensing or co-development agreements.

    Current Study

    Phase IIb head-to-head vs acyclovir with PPD (Thermo Fisher Scientific). 80 patients, 7 countries, 25 sites. Started January 2026. Primary readout: 7-8 months.

    80 patients (Phase IIb)7 EU countries, 25 sitesCRO: PPDStarted Jan 2026

    Partnership Options

    Regional or Global Licensing

    Post-Phase IIb readout licensing for specific territories or global rights

    Phase III Co-Development

    Joint investment in pivotal Phase III program. Shared risk/reward.

    Strategic Acquisition

    Full asset or company acquisition. IP + data room available.

    PATHWAY C

    ACRO-EYE & Easy-Dialysis

    For partners interested in ophthalmology or medical devices — Earlier-stage programs with significant market potential.

    ACRO-EYE™

    Tacrolimus ophthalmic solution for KCS. No direct equivalent. Co-development or licensing opportunity.

    Easy-Dialysis™

    Portable hemodialysis device. Prototype complete. Investment required for CE Marking.

    Request Partner Deck

    Complete the form to receive our non-confidential deck and Phase IIb study summary.

    Non-Confidential Deck
    Phase IIb Study Summary
    ceo@acsbiomed.com